Display Settings:

Format

Send to:

Choose Destination
    Breast Cancer Res. 2009;11(3):303. Epub 2009 May 18.

    Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

    Source

    Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA. bpschnei@iupui.edu

    Abstract

    Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

    PMID:
    19519950
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2716490
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk